Trans-4-hydroxy-lomustine
CAS: 56239-24-8
Ref. 3D-GCA23924
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- NSC 239717
- Urea, N-(2-chloroethyl)-N′-(trans-4-hydroxycyclohexyl)-N-nitroso-
- N-(2-Chloroethyl)-N′-(trans-4-hydroxycyclohexyl)-N-nitrosourea
- 1-(2-Chloroethyl)-3-(trans-4-hydroxycyclohexyl)-1-nitrosourea
- Urea, N-(2-chloroethyl)-N′-(4-hydroxycyclohexyl)-N-nitroso-, trans-
Trans-4-hydroxy-lomustine is a pyridinium salt of the anti-cancer drug lomustine, which is used to treat various types of cancers. It is administered orally and has been shown to have antitumour activity in animal studies. Trans-4-hydroxy-lomustine is metabolized by cytochrome P450 enzymes, including CYP2C8, CYP2C9, and CYP3A4. The major metabolites are monohydroxylated trans-4-hydroxy lomustine, which inhibits DNA synthesis and protein synthesis in cells. This drug also has stereoselective effects on tumor cells compared to normal tissue cells. Trans-4-hydroxy lomustine has high lipophilicity due to its quaternary ammonium group.